uniQure N.V.
US ˙ NasdaqGS ˙ NL0010696654

Introduction

This page provides a comprehensive analysis of the known insider trading history of Springhorn Jeremy P.. Insiders are officers, directors, or significant investors in a company. It is illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4. Despite these restrictions, academic research suggests that insiders - in general - tend to outperform the market in their own companies.

Average Trade Profitability

The average trade profitability is the average return of all the open market purchases made by the insider in the last three years. To calculate this, we examine every open-market, unplanned purchase made by the insider, excluding all trades that were marked as part of a 10b5-1 trading plan. We then calculate the average performance of those trades over 3, 6, and 12 months, averaging each of those durations to generate a final performance metric for each trade. Finally, we average all of the performance metrics to calculate a performance metric for the insider. This list only includes insiders that have made at least three trades in the last two years.

If this insiders trade profitability is "N/A", then the insider either has not made any open-market purchases in the last three years, or the trades they’ve made are too recent to calculate a reliable performance metric.

Update Frequency: Daily

See the list of most profitable insider traders.

Companies with Reported Insider Positions

The SEC filings indicate Springhorn Jeremy P. has reported holdings or trades in the following companies:

Security Title Latest Reported Holdings
US:QURE / uniQure N.V. Director 37,694
US:SYRS / Syros Pharmaceuticals, Inc. Chief Business Officer 94,000
How to Interpret the Charts

The following charts show the stock performance of securities subsequent to each open-market, non-planned trade made by Springhorn Jeremy P.. Non-planned trade are trades that were not made as part of a 10b5-1 trading plan. The stock performance is charted as cumulative percent change in share price. For example, if an insider trade was made on January 1, 2019, the chart will show the daily percent change of the security to the present day. If the share price were to go from $10 to $15 during this time, the cumulative percent change in share price would be 50%. A change in price from $10 to $20 would be 100%, and a change in price of $10 to $5 would be -50%.

Ultimately, we are trying to determine how closely the insider’s trades correlate to excess returns (positive or negative) in the share price in order to see if the insider is timing their trades to profit from insider information. Consider the situation where an insider was doing this. In this situation, we would expect either (a) positive returns after purchases, or (b) negative returns after sales. In the case of (a), the PURCHASE chart would show a series of upwardly sloping curves, indicating positive returns after each purchase transaction. In the case of (b), the SALE chart would show a series of downward sloping curves, indicating negative returns after each sale transaction.

However, this alone is not enough to draw conclusions. If, for example, the share price of the company was in a non-cyclical climb over many years, then we would expect all the post-purchase plots to be upwardly sloping. Likewise, non-cyclical declines over many years would result in downward sloping post-trade plots. Neither of these charts would suggest insider trading activity.

The strongest indicator would be a situation where the share price was extremely cyclical, and there were both positive signals in the PURCHASE chart and negative plots on the SALE chart. This situation would be highly suggestive of an insider that was timing trades to their financial advantage.

Insider Purchases QURE / uniQure N.V. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in QURE / uniQure N.V.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

QURE / uniQure N.V. Insider Trades
Insider Sales QURE / uniQure N.V. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in QURE / uniQure N.V.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
2025-06-20 QURE Springhorn Jeremy P. 2,112 14.4500 2,112 14.4500 30,518 49 13.2800 -2,471 -8.10
2024-06-13 QURE Springhorn Jeremy P. 2,231 5.1200 2,231 5.1200 11,423
2023-06-16 QURE Springhorn Jeremy P. 2,286 18.8800 2,286 18.8800 43,160
2023-02-27 QURE Springhorn Jeremy P. 384 20.4100 384 20.4100 7,837
2022-02-28 QURE Springhorn Jeremy P. 602 16.7000 602 16.7000 10,053
2021-03-02 QURE Springhorn Jeremy P. 505 37.5000 505 37.5000 18,938
2020-01-28 QURE Springhorn Jeremy P. 4 60.9400 4 60.9400 244
2020-01-28 QURE Springhorn Jeremy P. 803 62.2000 803 62.2000 49,947
2019-01-28 QURE Springhorn Jeremy P. 1,210 31.3200 1,210 31.3200 37,897

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

QURE / uniQure N.V. Insider Trades
Insider Purchases SYRS / Syros Pharmaceuticals, Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in QURE / uniQure N.V.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
2017-12-15 SYRS Springhorn Jeremy P. 15,000 9.0840 1,500 90.8400 136,260 124 136.5 68,490 50.26

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

SYRS / Syros Pharmaceuticals, Inc. Insider Trades
Insider Sales SYRS / Syros Pharmaceuticals, Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in QURE / uniQure N.V.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

SYRS / Syros Pharmaceuticals, Inc. Insider Trades
Insider Trading History

This table shows the complete list of insider trades made by Springhorn Jeremy P. as disclosed to the Securities Exchange Commission (SEC).

File Date Tran Date Form Ticker Security Code 10b5-1 Shares Remaining Shares Percent
Change
Share
Price
Tran
Value
Remaining
Value
2025-06-24 2025-06-20 4 QURE uniQure N.V.
Ordinary Shares
S - Sale -2,112 37,694 -5.31 14.45 -30,518 544,678
2025-06-13 2025-06-11 4 QURE uniQure N.V.
Ordinary Shares
A - Award 7,970 39,806 25.03
2024-06-21 2024-06-19 4 QURE uniQure N.V.
Ordinary Shares
A - Award 8,080 31,836 34.01
2024-06-17 2024-06-13 4 QURE uniQure N.V.
Ordinary Shares
S - Sale -2,231 23,756 -8.59 5.12 -11,423 121,631
2023-06-20 2023-06-16 4 QURE uniQure N.V.
Ordinary Shares
S - Sale -2,286 25,987 -8.09 18.88 -43,160 490,635
2023-06-20 2023-06-13 4 QURE uniQure N.V.
Ordinary Shares
A - Award 8,700 28,273 44.45
2023-03-01 2023-02-27 4 QURE uniQure N.V.
Ordinary Shares
S - Sale -384 19,573 -1.92 20.41 -7,837 399,485
2022-06-17 2022-06-15 4 QURE uniQure N.V.
Ordinary Shares
A - Award 9,080 19,957 83.48
2022-03-02 2022-02-28 4 QURE uniQure N.V.
Ordinary Shares
S - Sale -602 10,877 -5.24 16.70 -10,053 181,646
2022-02-28 2022-02-24 4 QURE uniQure N.V.
Stock Option (Right to Buy)
A - Award 2,645 2,645
2022-02-28 2022-02-24 4 QURE uniQure N.V.
Ordinary Shares
A - Award 1,534 11,479 15.42
2021-03-04 2021-03-02 4 QURE uniQure N.V.
Ordinary Shares
S - Sale -505 9,945 -4.83 37.50 -18,938 372,938
2021-03-01 2021-02-25 4 QURE uniQure N.V.
Stock Option (Right to Buy)
A - Award 4,107 4,107
2021-03-01 2021-02-25 4 QURE uniQure N.V.
Ordinary Shares
A - Award 2,382 10,450 29.52
2021-02-19 2021-02-17 4 SYRS Syros Pharmaceuticals, Inc.
Stock Option (right to buy)
A - Award 94,000 94,000
2020-03-02 2020-02-27 4 QURE uniQure N.V.
Stock Option (Right to Buy)
A - Award 3,620 3,620
2020-03-02 2020-02-27 4 QURE uniQure N.V.
Ordinary Shares
A - Award 2,063 8,068 34.35
2020-02-14 2020-02-13 4 SYRS Syros Pharmaceuticals, Inc.
Stock Option (right to buy)
A - Award 94,000 94,000
2020-01-30 2020-01-28 4 QURE uniQure N.V.
Ordinary Shares
S - Sale -803 6,005 -11.79 62.20 -49,947 373,511
2020-01-30 2020-01-28 4 QURE uniQure N.V.
Ordinary Shares
S - Sale -4 6,808 -0.06 60.94 -244 414,880
2019-11-12 2019-11-12 4 SYRS Syros Pharmaceuticals, Inc.
Common Stock
P - Purchase X 10,121 35,000 40.68 4.97 50,268 173,834
2019-11-12 2019-11-11 4 SYRS Syros Pharmaceuticals, Inc.
Common Stock
P - Purchase X 9,879 24,879 65.86 4.99 49,328 124,226
2019-02-14 2019-02-12 4 SYRS Syros Pharmaceuticals, Inc.
Stock Option (right to buy)
A - Award 75,000 75,000
2019-02-14 2019-02-12 4 SYRS Syros Pharmaceuticals, Inc.
Common Stock
A - Award 87,000 102,000 580.00
2019-01-30 2019-01-28 4 QURE uniQure N.V.
Ordinary Shares
S - Sale -1,210 6,812 -15.08 31.32 -37,897 213,352
2019-01-29 2019-01-25 4 QURE uniQure N.V.
Stock Option (Right to Buy)
A - Award 5,295 5,295
2019-01-29 2019-01-25 4 QURE uniQure N.V.
Ordinary Shares
A - Award 3,230 8,022 67.40
2018-01-30 2018-01-26 4 QURE uniQure N.V.
Stock Option (Right to Buy)
A - Award 6,390 6,390
2018-01-30 2018-01-26 4 QURE uniQure N.V.
Ordinary Shares
A - Award 4,792 4,792
2017-12-15 2017-12-15 4 SYRS Syros Pharmaceuticals, Inc.
Common Stock
P - Purchase 15,000 15,000 9.08 136,260 136,260
2017-11-14 2017-11-13 4 SYRS Syros Pharmaceuticals, Inc.
Stock Option (right to buy)
A - Award 50,000 50,000
2017-11-14 2017-11-13 4 SYRS Syros Pharmaceuticals, Inc.
Stock Option (right to buy)
A - Award 150,000 150,000
2017-09-26 2017-09-20 4 QURE uniQure N.V.
Stock Option (Right to Buy)
A - Award 10,000 10,000
2017-09-26 3 QURE uniQure N.V.
No securities are beneficially owned.
0
P
Open market or private purchase of non-derivative or derivative security
S
Open market or private sale of non-derivative or derivative security
A
Grant, award, or other acquisition of securities from the company (such as an option)
C
Conversion of derivative
D
Sale or transfer of securities back to the company
F
Payment of exercise price or tax liability using portion of securities received from the company
G
Gift of securities by or to the insider
K
Equity swaps and similar hedging transactions
M
Exercise or conversion of derivative security received from the company (such as an option)
V
A transaction voluntarily reported on Form 4
J
Other (accompanied by a footnote describing the transaction)